CVRx Announces Uptick for Hospital Reimbursements in 2025

Covered by Medicare and Medicaid

New Coding for Barostim Procedure

CVRx has announced a substantial increase in hospital reimbursements for its Barostim implantation procedure, effective fiscal year 2025. This is due to the reassignment of the procedure to Medicare Severity-Diagnosis Related Group (MS-DRG) 276, which carries a higher national average payment than the previous MS-DRGs (252, 253, 254) assigned in fiscal year 2024. This change is expected to lead to a significant increase in hospital revenue for the Barostim procedure.

The Barostim therapy is a minimally invasive procedure that treats drug-resistant hypertension, a condition in which blood pressure remains dangerously high despite the use of multiple medications. The device is implanted under the skin and works by stimulating the baroreceptors, sensors that regulate blood pressure.

"We are pleased with this positive development, which we believe will lead to increased access to the Barostim therapy for patients with drug-resistant hypertension," said Nadim Yared, President and CEO of CVRx. "This change in coding recognizes the value of the Barostim therapy and its potential to improve the lives of patients with this difficult-to-treat condition."

CVRx anticipates that the increased reimbursement will incentivize more hospitals to offer the Barostim therapy. The company plans to continue to work with CMS and other payers to ensure that patients have access to the therapy.